$GMED · GLOBUS MEDICAL INC
Globus Medical reported Q3 FY2026 results: net sales of $763.7M, down 0.7% as-reported (down 0.5% constant currency). GAAP net income was $141.2M, GAAP diluted EPS $1.04 (up 18.2%), and non-GAAP diluted EPS $1.23 (up 4.4%). The company cut full-year 2026 revenue guidance to $3.09B from $3.18B-$3.22B, while reaffirming non-GAAP EPS guidance of $4.95-$5.05. The board authorized a $500M increase to the repurchase program, leaving ~$611M available.
- Q3 net sales $763.7M, down 0.7% as-reported and 0.5% constant currency.
- GAAP diluted EPS $1.04, up 18.2%; non-GAAP diluted EPS $1.23, up 4.4%.
- FY2026 revenue guidance cut to $3.09B from $3.18B-$3.22B.
- Board authorized $500M buyback increase; ~$611M remains available.
- Enabling Technologies revenue grew 24% with 73% more robot/navigation units deployed.
Extended-hours trading shows GMED at $77.00, down 5.54% from the $81.52 regular close, reflecting the revenue guidance cut despite the buyback increase.
A guidance cut paired with a $500M buyback increase signals management confidence in cash generation despite slowing top-line growth.
No sector context available.
Revenue declined 0.7% with U.S. Spine facing difficult prior-year comparables (2% growth vs double-digit prior year); international sales fell 5.7% as-reported.